TP53 and B-cell chronic lymphocytic leukemia: Similarly, while the PFS benefit of Acala was sustained compared to IdelaR/BR-treated patients, the median PFS for patients with TP53 aberrant CLL was 45.5 months, and not reached for patients without del[17p] and/or TP53 mutation [43].